抗乙肝病毒对肝癌TACE术后复发转移的临床疗效及免疫功能研究

The clinical effect and immune function of anti HBV on recurrence and metastasis of liver cancer after transarterial chemoembolization

目的探讨接受TACE治疗的乙肝病毒相关性肝癌患者在术后进行抗病毒治疗的临床效果及免疫功能的影响。方法选取本科室在2015年1月至2017年2月期间收治的86例均接受TACE治疗的乙肝表面抗原阳性肝癌患者。根据术后是否应用核苷(酸)类似物抗病毒治疗,分为实验组(n=53)和对照组(n=33),比较两组患者的近期疗效、1年内肝癌复发率、免疫功能、及肝功能。结果实验组患者近期疗效优于对照组(79.8%vs 54.5%,P=0.025),且1年复发率更低(43.4%vs 60.6%,P=0.001);实验组患者CD3+、NK、CD4+/CD8+较对照组增高明显(P<0.05);实验组患者的肝功能改善情况优于对照组(P<0.05)。结论接受TACE治疗的乙肝病毒相关性肝癌患者术后进行抗病毒治疗,可以改善患者预后,提高患者免疫能力,改善肝功能。

Objective To investigate the clinical effects and immune function of antiviral therapy in patients with hepatitis B virus?related liver cancer receiving transarterial chemoembolization(TACE).Methods 86 patients with HBsAg positive liver cancer treated in our department from January 2015 to February 2017 were selected and all patients were treated with TACE.According to the application of nucleoside(acid)analogues in antiviral treatment,they were divided into experimental group(n=53)and control group(n=33).The short?term efficacy,recurrence rate,immune function and liver function in 1 years were compared between the two groups.Results The short?term efficacy of the experimental group was better than that of the control group(79.8%vs 54.5%,P=0.025),and the 1?year recurrence rate was lower(43.4%vs 60.6%,P=0.001);the experimental group patients CD3+,NK,CD4+/CD8+was significantly higher than the control group(P<0.05).The improvement of liver function in the experimental group was better than that in the control group(P<0.05).Conclusion Anti?viral treatment of patients with hepatitis B virus?related liver cancer receiving TACE can improve the prognosis,improve the patient??s immunity and improve liver function.